Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Formosa PharmaceuticalsTPE:6838 -1.67%48 Days Payable is 37.22 as of Dec. 2025, which is 48% above its 10-year median of 25.20. GuruFocus rates TPE:6838 with a GF Score™ of 48/100 and a GF Value™ of NT$14.25 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 701 Biotechnology companies, Formosa Pharmaceuticals ranks worse than 84.02% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6838 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Formosa Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formosa Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formosa Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Formosa Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Formosa Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formosa Pharmaceuticals (TPE:6838) has a Days Payable of 37.22 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Formosa Pharmaceuticals and its competitors. This is 48% above median its historical median of 25.20. Over the past decade, Formosa Pharmaceuticals' Days Payable has ranged from 25.20 to 26.13. According to the industry distribution chart, Formosa Pharmaceuticals ranks #589 out of 701 companies in the Biotechnology industry, placing it in the top 84%.
Is Formosa Pharmaceuticals' Days Payable too high?
Formosa Pharmaceuticals' current Days Payable of 37.22 is 48% above median its 10-year median of 25.20. Over the past 10 years, this metric has ranged from a low of 25.20 to a high of 26.13. The Biotechnology industry median Days Payable is 112.84. Formosa Pharmaceuticals' value of 37.22 is 67% below this industry median. Based on the distribution chart, Formosa Pharmaceuticals ranks #589 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Formosa Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Formosa Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formosa Pharmaceuticals ranks #589 out of 701 companies for Days Payable. This places Formosa Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 112.84. Formosa Pharmaceuticals' value of 37.22 is 67% below this benchmark. Historically, Formosa Pharmaceuticals' own Days Payable has ranged from 25.20 to 26.13 over the past decade. While the company's 10-year median is 25.20 vs. the industry median of 112.84, Formosa Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formosa Pharmaceuticals's current Days Payable of 37.22 is 67% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Formosa Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formosa Pharmaceuticals's current Days Payable is 37.22, which is 48% above median its own 10-year median of 25.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formosa Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Formosa Pharmaceuticals (TPE:6838) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.25, compared to a current price of NT$23.60 — trading 65.6% above its estimated fair value. The current Days Payable is 37.22, which is 48% above median its 10-year median of 25.20 and 67% below the Biotechnology industry median of 112.84. Formosa Pharmaceuticals' overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Formosa Pharmaceuticals (TPE:6838), the current Days Payable is 37.22 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formosa Pharmaceuticals (TPE:6838) Overvalued in 2026?
Based on GuruFocus' analysis, Formosa Pharmaceuticals stock appears to be overvalued.
The current stock price of NT$23.60 is trading 65.6% above its estimated GF Value™ of NT$14.25.
GuruFocus considers Formosa Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for TPE:6838:
Days Payable: 37.22 (48% above median its 10-year median of 25.20)
GF Value™: NT$14.25 vs. price of NT$23.60 (65.6% above fair value)
Industry Position: 67% below the Biotechnology median (#589 of 701)
No single metric tells the full story. See the TPE:6838 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formosa Pharmaceuticals Inc is engaged in new drug development and transfers. Its Product pipeline includes TSY-110, TSY-120, TSY-310, APP13007 and APP13002.
48GF Score
Get the complete analysis for TPE:6838
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6838 has been successfully added to your 
